Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity.
EEG
aphasia
oncology
Journal
BMJ neurology open
ISSN: 2632-6140
Titre abrégé: BMJ Neurol Open
Pays: England
ID NLM: 101775450
Informations de publication
Date de publication:
2020
2020
Historique:
accepted:
20
05
2020
entrez:
8
3
2021
pubmed:
9
3
2021
medline:
9
3
2021
Statut:
epublish
Résumé
Chimeric antigen receptor-modified T cells (CAR-T) have emerged as a promising immunotherapeutic approach in relapsed/refractory haematolgical malignancies. Broader application is limited by unique toxicities, notably, neurotoxicity (NTX). Language dysfunction is among the most frequent symptoms of NTX, the underlying mechanisms of which remain to be elucidated. Electroencephalogram (EEG) is an important tool to monitor for NTX and may provide insights into language dysfunction. We aimed to characterise language dysfunction and define electroencephalographic signatures after CAR-T cell therapy. We reviewed the clinical presentation and EEG findings of 20 adult patients presenting with language dysfunction after CAR-T cell infusion. The cohort included a subset of patients treated with investigational CD19-directed CAR-T cells for non-Hodgkin's lymphoma (n=17), acute lymphoblastic leukaemia (n=1), follicular lymphoma (n=1) and chronic lymphocytic leukaemia (n=1). Language dysfunction presented within 14 days of CAR-T cell infusion in 16 (84%) patients. Ten (50%) patients had mild word-finding difficulties and 10 (50%) had marked dysphasia with profound word-finding difficulties; the latter were all associated with generalised rhythmic delta activity or generalised periodic discharges on EEG. Language dysfunction after CAR-T cell therapy is associated with generalised EEG abnormalities.
Identifiants
pubmed: 33681787
doi: 10.1136/bmjno-2020-000054
pii: bmjno-2020-000054
pmc: PMC7871716
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e000054Commentaires et corrections
Type : ErratumIn
Type : ErratumIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: JD is a consultant for Blue Earth Diagnostics and Unum Therapeutics. JD is an author for UpToDate and received royalties from Wolters Kluwer.
Références
Neurology. 2012 Nov 6;79(19):1951-60
pubmed: 23035068
Blood. 2019 May 16;133(20):2212-2221
pubmed: 30808634
JAMA Neurol. 2017 Feb 1;74(2):181-188
pubmed: 27992625
Brain. 2019 May 1;142(5):1334-1348
pubmed: 30891590
J Clin Neurophysiol. 2013 Feb;30(1):1-27
pubmed: 23377439
Oncologist. 2016 May;21(5):608-17
pubmed: 27009942
Neurology. 2018 Jul 31;91(5):227-229
pubmed: 29959264
Nat Rev Clin Oncol. 2018 Jan;15(1):31-46
pubmed: 28857075
Crit Care. 2017 Apr 14;21(1):89
pubmed: 28407743
Clin Neurophysiol Pract. 2017 May 26;2:107-118
pubmed: 30214982
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
AJNR Am J Neuroradiol. 2019 May;40(5):766-768
pubmed: 31048298